RATIONALE: Hypersensitivity reactions to iodinated contrast media (ICM) are a common problem and can cause anaphylaxis. The clinical utility of skin testing for ICM reactions is uncertain. METHODS: Retrospective analysis was done of data from 47 patients (18 males, 29 females, average age 55 years) with a history of hypersensitivity reactions to ICM referred to Vilnius University Hospital from 2014 to 2017 . Skin prick (SPT) and intradermal tests (IDM) with ICM were performed according to the EAACI guidelines including assessment of ICM iohexol, iopromide, diatrizoate, iodixanol, and iopamidol. RESULTS: Cutaneous symptoms were most common (55.6%) followed by cardiovascular symptoms (17.5%), respiratory symptoms (9.5%) and gastrointestinal symptoms (7.9%) with some (9.5%) nonspecific symptoms. SPT were negative in all patients. Seven out of 47 (14.9%) patients had positive IDT. 3 patients had positive reactions to 2 or more ICM. Reactions to ICM were not more severe in patients with positive skin test results. Clinical patterns of IDT positive patients did not differ from patients with negative skin tests. Five of 23 patients tested less than one year after the reaction had a positive IDT, while 2 of 24 patients having a reaction to ICM more than 1 year prior were positive (p>0.05). CONCLUSIONS: Allergy to ICM was seldom produced positive IDT in patients with suspected ICM hypersensivity ICM. Cutaneous symptoms were most frequent form of ICM hypersensitivity reaction irregardless of skin test results. with positive and negative skin tests.
George Washington University School of Medicine, Washington, DC. RATIONALE: Hypersensitivity reactions to iodinated contrast media (ICM) are a common problem and can cause anaphylaxis. The clinical utility of skin testing for ICM reactions is uncertain. METHODS: Retrospective analysis was done of data from 47 patients (18 males, 29 females, average age 55 years) with a history of hypersensitivity reactions to ICM referred to Vilnius University Hospital from 2014 to 2017 . Skin prick (SPT) and intradermal tests (IDM) with ICM were performed according to the EAACI guidelines including assessment of ICM iohexol, iopromide, diatrizoate, iodixanol, and iopamidol. RESULTS: Cutaneous symptoms were most common (55.6%) followed by cardiovascular symptoms (17.5%), respiratory symptoms (9.5%) and gastrointestinal symptoms (7.9%) with some (9.5%) nonspecific symptoms. SPT were negative in all patients. Seven out of 47 (14.9%) patients had positive IDT. 3 patients had positive reactions to 2 or more ICM. Reactions to ICM were not more severe in patients with positive skin test results. Clinical patterns of IDT positive patients did not differ from patients with negative skin tests. Five of 23 patients tested less than one year after the reaction had a positive IDT, while 2 of 24 patients having a reaction to ICM more than 1 year prior were positive (p>0.05). CONCLUSIONS: Allergy to ICM was seldom produced positive IDT in patients with suspected ICM hypersensivity ICM. Cutaneous symptoms were most frequent form of ICM hypersensitivity reaction irregardless of skin test results. with positive and negative skin tests.
181
Being ''SCIT'' Careful in the Spring: Analyzing Patterns of Immunotherapy-Induced Anaphylaxis Over the Years Jason A. Ohayon, MD FAAAAI, Stephanie L. Vakaljan, BSc., Vince Wu, and Sydney A. Scheffler, BSc; Hamilton Allergy, Hamilton, ON, Canada. RATIONALE: Subcutaneous immunotherapy (SCIT) is an effective treatment for allergic individuals. Despite SCIT success, anaphylaxis remains a risk, albeit less than 1% of injections. We aimed to characterize patterns of anaphylaxis in a community clinic administering SCIT, to help identify patterns of increased risk. METHODS: A retrospective chart review was carried out over a 15-year period (January 1, 2004 to August 15, 2018). Data was collected on patients who had sustained a SCIT-induced anaphylaxis. Demographic profiles, timing and reaction details were analyzed. A 5-year subset (2012-2017) was used to calculate total average injection rates in May and November. RESULTS: Sixty patients were identified with 64 total reactions. Thirtyfour of 64 (53%) were female. One female patient sustained 3 anaphylactic reactions and 2 males sustained 2 reactions. Forty-one (68%) patients were polysensitized (2, 3, 4, or 5 IT allergens) and 19 were monosensitized. April (10/64) and May (15/64) were the most active months for anaphylaxis, totaling 39% of yearly reactions. Fifty-six of 64 (88%) reactions occurred in the afternoon. The mean afternoon injections in May were 317/378 (84%). The mean afternoon injections in November were 35/ 150 (77%). Twenty-five (42%) patients discontinued SCIT following anaphylaxis; 35 (58%) remained on immunotherapy. CONCLUSIONS: SCIT induced anaphylactic reactions were most common in the Spring season (April-May). More anaphylactic reactions occurred in the PM, although consistent with the ratio of PM/total daily injections. Anaphylaxis induced a high drop-out rate, yet the majority continued on SCIT. Polysensitized patients receiving SCIT in Spring afternoons may benefit closer monitoring for anaphylaxis. 1 Kobe City Medical Center General Hospital, Kobe, Japan, 2 Torii Pharmaceutical Co., Ltd, Tokyo, Japan. RATIONALE: Since 2015, our clinic has used a standardized house-dust mite extract (SM) for subcutaneous immunotherapy (SCIT) instead of nonstandardized house dust extract (nSM) for patients with house dust mite (HDM) allergies. We hypothesized that SM is superior to nSM for SCIT. METHODS: This was a non-interventional, retrospective study. We included 13 patients with HDM allergy. These patients initially underwent SCIT using nSM and were later switched to SM. We evaluated the introduction time, safety, and efficacy of SM. We assessed the introduction time and safety in these target cases and compared them to those of patients newly introduced to SM for SCIT. Efficacy was assessed by monitoring changes in the allergic rhinitis symptom-medication and asthma treatment scores, pre-to post-SM exposure. Changes in HDM-specific antibody titer were also measured. RESULTS: The mean introduction period for the target cases was 4.2 days, which was significantly shorter than that for patients who were newly introduced to SM (6.2 days). Although it was not significant, systemic reaction rates of target cases (15%) tended to be lower than those of newly introduced cases (44%). The allergic rhinitis symptom-medication score significantly decreased from 2.9 to 1.7(p 5 0.03), although there was no significant improvement in asthma treatment score (from 207 to 137). We observed increases in HDM-specific IgG4 titer after switching to SM compared to titers taken before switching. CONCLUSIONS: For SCIT, switching from nSM to SM appears to shorten the introduction period and is associated with high safety and enhanced therapeutic effects.
